Skip to main content

Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Completed · Phase 3 · NCT04708782

Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease

At a glance

Research payments reported, 2025
$4.5M
U.S. investigators named
93
Sites paid
88
Planned or actual enrollment
598

About the trial

Sponsor
United Therapeutics
Tested
Placebo (drug), Inhaled Treprostinil (drug), Treprostinil Ultrasonic Nebulizer (device)
Dates
Started 2021-06-01; completion 2026-02-02
Results posted
Not yet

Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.

From ClinicalTrials.gov, last updated 2026-05-05. Full record, eligibility and contacts (opens in a new tab)

Industry funding

United Therapeutics Corporation reported $4.5M in research payments for this study in 2025 (1,575 payments).

Products named: Tyvaso

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.